Analyst Views Mixed As Amgen's Weight Loss/Diabetes Drug MariTide Shows Promise But Has Dose Issues
1. AMGN's MariTide shows up to 20% weight loss in obesity without T2D. 2. No new safety signals identified; tolerability aligns with GLP-1 class. 3. Phase 3 MARITIME program initiated to explore chronic weight management. 4. Weight loss accompanied by reductions in cardiovascular risk factors. 5. Analysts express caution on weight loss estimates vs. expectations.